Form 4: Theravance Biopharma Executive Reports Stock Transaction
Insider Transaction (Form 4)
Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS of Theravance Biopharma, Inc., reported multiple transactions in common stock on September 23, 2026.
Summary
- Disposition to the issuer: disposed of 124,414 Ordinary Shares on September 23, 2026; holds 89,062 after (Direct).
- Disposition to the issuer: disposed of 89,062 Ordinary Shares on September 23, 2026 (Direct).
- Disposition to the issuer: disposed of 150,000 Share Option (Right to Buy) on September 23, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Rhonda Farnum — Officer (SVP, COMM & MEDICAL AFFAIRS)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 124,414 | — | — | 89,062 |
| 2026-09-23 | Disposition to the issuer | Ordinary Shares | 89,062 | — | — | 0 |
| 2026-09-23 | Disposition to the issuer | Share Option (Right to Buy) | 150,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-23 | Disposition to the issuer (124,414 shares) |
| 2026-09-23 | Disposition to the issuer (89,062 shares) |
| 2026-09-23 | Disposition to the issuer (150,000 shares) |
Keywords
insider transaction, Form 4, TBPH, Theravance Biopharma, Inc., neutral, Rhonda Farnum
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.